Featured
-
-
Article
| Open AccessMorpholino-driven blockade of Dkk-1 in osteosarcoma inhibits bone damage and tumour expansion by multiple mechanisms
- Simin Pan
- , Michael Cesarek
- & Carl A. Gregory
-
Article
| Open AccessThe association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa)
- Martin Eichler
- , Susanne Singer
- & Markus K. Schuler
-
Article |
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
- Brian Schulte
- , Nisha Mohindra
- & Mark Agulnik
-
Article
| Open AccessEWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma
- Shaohui He
- , Quan Huang
- & Jianru Xiao
-
Article
| Open AccessDetection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group
- David S. Shulman
- , Kelly Klega
- & Brian D. Crompton
-
Article |
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
- Elisabeth F. P. Peterse
- , Bertine Niessen
- & Judith V. M. G. Bovée
-
Clinical Study
| Open AccessComprehensive geriatric assessment in 326 older women with early breast cancer
- D O Okonji
- , R Sinha
- & A Ring
-
Molecular Diagnostics
| Open AccessPost-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas
- Nadège Presneau
- , Laure Alice Duhamel
- & Malihe Eskandarpour
-
Translational Therapeutics
| Open AccessLoss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis
- Alison Roos
- , Laura Satterfield
- & Jason T Yustein
-
Clinical Study
| Open AccessAssessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
- J Guo
- , J O Glass
- & W E Reddick
-
Clinical Study
| Open AccessClinical nomogram to predict bone-only metastasis in patients with early breast carcinoma
- Yann Delpech
- , Sami I Bashour
- & Nuhad K Ibrahim
-
Translational Therapeutics
| Open AccessCaspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing’s sarcoma
- Zhigang Kang
- , Seth D Goldstein
- & Liang Cao
-
Clinical Study
| Open AccessLong-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study
- M M Fidler
- , C Frobisher
- & M M Hawkins
-
Clinical Study
| Open AccessRecurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review
- N C Daw
- , A J Chou
- & W W Huh
-
Translational Therapeutics
| Open AccessPrevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
- X Yang
- , P Yang
- & Z Duan
-
Translational Therapeutics
| Open AccessPreclinical validation of Aurora kinases-targeting drugs in osteosarcoma
- E Tavanti
- , V Sero
- & M Serra
-
Translational Therapeutics
| Open AccessSurface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
- J PosthumaDeBoer
- , S R Piersma
- & M N Helder
-
Molecular Diagnostics
| Open AccessFunctional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
- S U Lauvrak
- , E Munthe
- & O Myklebost
-
Translational Therapeutics
| Open AccessCXCR7-mediated progression of osteosarcoma in the lungs
- E Goguet-Surmenian
- , P Richard-Fiardo
- & H Schmid-Antomarchi
-
Translational Therapeutics
| Open AccessY-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma
- Y Fujiwara-Okada
- , Y Matsumoto
- & Y Iwamoto
-
Translational Therapeutics
| Open AccessSystemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
- M L Broadhead
- , C R Dass
- & P F M Choong
-
Letter to the Editor
| Open AccessReply: Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria
- T Hamaoka
- , C M Costelloe
- & N T Ueno
-
Molecular Diagnostics
| Open AccessBasic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1–PI3K–Rac1 pathway
- S Kamura
- , Y Matsumoto
- & Y Iwamoto
-
Molecular Diagnostics
| Open AccessOsteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone
- L Endo-Munoz
- , A Cumming
- & N A Saunders